Teh BW - Search Results

1

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.

Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Liet Hing MN, Harrison SJ, Kesselheim AS, Teh BW. Reynolds G, et al. Among authors: teh bw. Blood Adv. 2023 Oct 10;7(19):5898-5903. doi: 10.1182/bloodadvances.2023010539. Blood Adv. 2023. PMID: 37467036 Free PMC article.

2

A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease.

Teh BW, Khot AS, Harrison SJ, Prince HM, Slavin MA. Teh BW, et al. Transpl Infect Dis. 2013 Aug;15(4):E134-8. doi: 10.1111/tid.12106. Epub 2013 Jun 23. Transpl Infect Dis. 2013. PMID: 23790037

3

Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection.

Teh BW, Harrison SJ, Pellegrini M, Thursky KA, Worth LJ, Slavin MA. Teh BW, et al. Blood Rev. 2014 Mar;28(2):75-86. doi: 10.1016/j.blre.2014.01.004. Epub 2014 Feb 10. Blood Rev. 2014. PMID: 24582081 Review.

4

Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies.

Teh BW, Teng JC, Urbancic K, Grigg A, Harrison SJ, Worth LJ, Slavin MA, Thursky KA. Teh BW, et al. Haematologica. 2015 Jan;100(1):e28-31. doi: 10.3324/haematol.2014.114025. Epub 2014 Oct 10. Haematologica. 2015. PMID: 25304609 Free PMC article. No abstract available.

5

Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.

Teh BW, Worth LJ, Harrison SJ, Thursky KA, Slavin MA. Teh BW, et al. Support Care Cancer. 2015 Jul;23(7):1901-6. doi: 10.1007/s00520-014-2550-3. Epub 2014 Dec 10. Support Care Cancer. 2015. PMID: 25487843 Free PMC article.

6

Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy.

Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Teh BW, et al. Br J Haematol. 2015 Oct;171(1):100-8. doi: 10.1111/bjh.13532. Epub 2015 Jun 24. Br J Haematol. 2015. PMID: 26105211 Free article.

7

Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization.

Teh BW, Slavin MA, Harrison SJ, Worth LJ. Teh BW, et al. Expert Rev Anti Infect Ther. 2015;13(11):1325-36. doi: 10.1586/14787210.2015.1083858. Epub 2015 Aug 31. Expert Rev Anti Infect Ther. 2015. PMID: 26489539 Review.

8

Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies.

Teh BW, Harrison SJ, Worth LJ, Slavin MA. Teh BW, et al. Leuk Lymphoma. 2016 Jul;57(7):1719-22. doi: 10.3109/10428194.2015.1106538. Epub 2016 Jan 4. Leuk Lymphoma. 2016. PMID: 26727243 No abstract available.

9

Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.

Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA. Teh BW, et al. Eur J Cancer. 2016 Nov;67:21-37. doi: 10.1016/j.ejca.2016.07.025. Epub 2016 Sep 1. Eur J Cancer. 2016. PMID: 27592069 Review.

10

Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy.

Teh BW, Harrison SJ, Slavin MA, Worth LJ. Teh BW, et al. Eur J Haematol. 2017 Feb;98(2):149-153. doi: 10.1111/ejh.12813. Epub 2016 Oct 10. Eur J Haematol. 2017. PMID: 27717026

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters